Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers

NCT05308680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 336

Last updated 2022-05-09

No results posted yet for this study

Summary

The aim of the study is to prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.

Conditions

  • Myocardial Injury
  • Vaccine Adverse Reaction
  • COVID-19

Interventions

BIOLOGICAL

BNT162b2

Administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19

Sponsors & Collaborators

  • Shaare Zedek Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2022-01-24
Completion
2022-03-28
FDA Drug
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05308680 on ClinicalTrials.gov